2025 outlook The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance: Prior guidance August 6 update Change at midpoint Y/Y growth rate Total revenue $3.070 - $3.120 billion $3.130 - $3.170 billion $55.0 million 14% Screening $2.390 - $2.425 billion $2.440 - $2.470 billion $47.5 million 17% Precision Oncology $680 - $695 million $690 - $700 million $7.5 million 6% Adjusted EBITDA $425 - $455 million $455 - $475 million $25.0 million 44% Second-quarter 2025 conference call & webcast Company management will host a conference call and webcast on Wednesday, August 6, 2025, at 5 p.m. ET to discuss second-quarter 2025 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties. Non-GAAP disclosure In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents the following non-GAAP measures: Core revenue — Core revenue is calculated to adjust for recent acquisitions and divestitures and foreign currency exchange rate fluctuations. Revenue from recent acquisitions is adjusted for the 12 months following acquisition when the periods are not comparable. To exclude the impact of change in foreign currency exchange rates from the prior period under co

later in the release …

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.